The firms entered into a merger agreement in February for Novo Holdings to acquire Catalent in an all-cash transaction worth $16.5 billion. That deal still expects to close toward the end of ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena plots its U.S. debut. Catalent is selling its oral solids development ...

A Catalent spokesperson reiterated the company's position on the deal in a statement on Friday to Reuters in response to the letter: "Novo Holdings’ pending acquisition of Catalent will further ...

Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to contract manufacturer Ardena. Financial details of the agreement ...

(Reuters) - Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to private contract drug manufacturer Ardena, the companies said on ...

Earnings Estimate Revisions for Catalent For the fiscal year ending June 2025, this maker of drug delivery technologies is expected to earn $1.36 per share, which is a change of 444% from the year ...

U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo Nordisk’s parent foundation would acquire Catalent, a leading ...

Pace Life Sciences, a division of the broader Pace organization, has acquired a laboratory in Morrisville from Catalent (NYSE: CTLT) that focuses on analytical services. Catalent is a contract ...

SOMERSET, N.J. - Catalent, Inc. (NYSE: NYSE:CTLT), a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, has reached a ...

Robert W. Baird analyst Eric Coldwell downgraded the rating on Catalent (CTLT – Research Report) to a Hold today, setting a price target of $63.50. Eric Coldwell has given his Hold rating due to ...

Fintel reports that on September 24, 2024, Baird downgraded their outlook for Catalent (NYSE:CTLT) from Outperform to Neutral ...

(RTTNews) - Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, Monday said it has agreed to sell its ...